Flow Pharma Receives Patent Allowance for Universal Ebola Treatment Using Siltuximab
核心洞察
Flow Pharma (搜索) announced U.S. patent allowance for a broad-spectrum Ebola treatment using siltuximab, a monoclonal antibody that targets toxins released by all Ebola virus (搜索) strains.
The patented approach covers both traditional intravenous administration and controlled-release delivery via the company's proprietary FlowVax™ microsphere platform.
Preclinical studies demonstrated siltuximab's effectiveness in treating mice following intentional Ebola virus (搜索) exposure, representing the first BSL-4 lab testing of this antibody for Ebola treatment.
Flow Pharma (搜索) announced that its U.S. patent application has been allowed for issuance, covering a broad-spectrum treatment for Ebola virus (搜索) infections using the company's proprietary microsphere delivery technology. The patent represents a significant advancement in Ebola therapeutics, as it addresses all known Ebola virus strains rather than targeting specific variants.
Novel Approach Targets Universal Ebola Toxin
Unlike currently available therapies designed for specific Ebola strains, Flow Pharma (搜索)'s patented approach utilizes the monoclonal antibody siltuximab, which binds to a toxin released after infection with all Ebola virus (搜索) strains. In preclinical studies, the company demonstrated that siltuximab effectively treated mice following intentional exposure to Ebola virus.
"We were the first group in the world to test siltuximab in a BSL-4 lab as a treatment for Ebola infection," said Dr. Reid Rubsamen, founder and CEO of Flow Pharma (搜索). "Rather than targeting only a specific viral strain, the treatment described in our invention is applicable across all known Ebola virus (搜索) strains."
Dual Delivery Platform Enhances Therapeutic Potential
The patent covers both traditional intravenous administration of siltuximab and controlled-release delivery using Flow Pharma (搜索)'s proprietary FlowVax™ microsphere platform. This microsphere technology is designed to prolong therapeutic exposure following injection, potentially improving treatment outcomes.
Miguel Yanez, a member of the Flow Pharma (搜索) Board of Directors, noted that "siltuximab for intravenous administration has been approved for a rare disease application and has been sold for that indication by another company for over 10 years." He added that with composition of matter patents for siltuximab now expiring, the company hopes to achieve FDA approval for this new indication.
Timing Coincides with Current Outbreak
The patent allowance announcement comes during an ongoing Ebola outbreak involving a strain with no known antiviral therapy, underscoring the urgent need for broad-spectrum treatments. Dr. Rubsamen emphasized that the company has published its data and expressed excitement about expanding their intellectual property portfolio to 10 patents and 19 patents pending.
Broader Platform Applications
Beyond Ebola therapeutics, Flow Pharma (搜索) has developed vaccine candidates targeting Ebola, Marburg (搜索), COVID-19 (搜索), and multiple oncology indications using its patented FlowVax™ adjuvanted microsphere peptide vaccine platform. The platform uses naturally occurring peptide antigens packaged within synthetic biodegradable microspheres designed to stimulate targeted T-cell responses.
The company's vaccine platform is fully synthetic and does not use mRNA, DNA transcription, live viral vectors, or animal-derived products. Flow Pharma (搜索)'s vaccine designs are based on analysis of immune responses observed in individuals who naturally overcame viral infections and cancer.
Flow Pharma (搜索) believes the FlowVax™ platform's room-temperature stability, low manufacturing cost, and applicability across infectious disease and oncology positions it for biodefense, pandemic preparedness, and cancer immunotherapy applications. The platform targets multiple disease areas including triple-negative breast cancer (搜索) and glioblastoma (搜索) in addition to infectious diseases like influenza (搜索).